Searched for
DIVIS LABORATORIES EARNINGS
Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...- More women CXOs join India’s million-dollar pay club as domestic firms lead compensation growthNine women now earn over one million dollars annually as C-suite executives. Domestic companies are leading this rise, reflecting a focus o...
- For both the compulsive trader and careful investor: 25 stocks to watch if risk appetite returns; some with upside potential, some notIf the price of crude oil softens, Indian equities may again see a risk-on phase. Tariff concerns are no longer the central issue; the larg...
- Divi's Laboratories Q4 Results: Cons PAT grows 13% YoY to Rs 751 crore, revenue up 10%; Rs 30 per share dividend announcedDivi's Laboratories Q4 Results: Divi's Laboratories announced strong financial results for the March quarter. Net profit rose 13% to Rs 751...
- Mankind, other pharma stocks rally up to 7%; Nifty Pharma scales fresh peak. What lies ahead?Pharma stocks surged on Wednesday, supported by strong earnings and a weakening rupee, even as Sensex and Nifty traded lower. The Nifty Pha...
- Tariff threat ain't over yet! Sun Pharma, other pharma stocks plunge up to 6%Pharma stocks fell after reports that the Trump administration may impose tariffs—potentially up to 100%—on drugmakers not ensuring low pri...
- Divi’s Laboratories Q2 Results: Cons profit jumps 35% YoY to Rs 689 crore, revenue up 16%Divi's Laboratories reported a robust financial performance for the second quarter of FY26, with consolidated net profit soaring by 35% yea...
- Divi’s Laboratories Q2 Results: Company posts 47% jump in net profit in Q2FY25Divi's Laboratories witnessed a 46.6% surge in profit, reaching Rs. 510 crores in Q2FY25, fueled by robust growth in their custom synthesis...
- Divi's Laboratories Q4 Results: Cons PAT soars 68% YoY to Rs 538 crore; dividend declared at Rs 30 per shareDivi's Laboratories Q4 Results: Net profit stood at Rs 321 crore in the corresponding quarter of the last financial year. The consolidated ...
- Divis Labs Q3 Results: Profit rises 17% YoY to Rs 358 croreRevenue from operations in the reporting period increased 9% year-on-year to Rs 1,855 crore, compared with Rs 1708 crore in the correspondi...
- Divi's Labs Q3 Results: Profit jumps 92% YoY to Rs 902 crore, beats estimatesRevenue from operations came in at Rs 2493.24 crore, up 46.53 per cent against Rs 1701.44 crore in the year-ago quarter.
- Divi's Labs shares fall 9% post Sept quarter numbers; here's whyWe envisage near term pressures growin for Divi's Labs, with rising raw material prices, logistical issues and declining generics business,...
- Divi's Labs Q2 results: Net profit jumps 46% YoY to Rs 520 croreFor the current quarter, Divi’s Labs witnessed a forex loss of Rs 16 crore against a gain of Rs 13 crore.
- Buy Divi's Laboratories, target Rs 1,670: SharekhanBuy Divi's Laboratories Ltd. at a price target of Rs 1670.
- Divi’s Laboratories nosedives 20%, hits 52-week low on USFDA’s import alertIn a filing to BSE, the drug marker said that the USFDA has exempted the company from making ten drugs.
- Divis Lab Q2 Net up 11 pc at Rs 118 croreDivis Laboratories Ltd today said its net profit rose by 11.23 per cent year-on-year to Rs 117.97 crore for the second quarter ended Septem...
- Divi's Lab rises on reports of MSCI inclusionShares of Indian drug maker Divi's Laboratories rose over 2 percent on Tuesday, on reports of a possible inclusion in the MSCI index.
- Divi's Laboratories Q4 profit up 24 pc at Rs 217 crDivi's Laboratories today said its consolidated net profit rose by 23.81 per cent to Rs 216.91 crore for the fourth quarter ended December ...
- Divi's Labs rise over 3 pc on strong Q4 numbersShares of drugmaker Divi's Laboratories rose as much as 3.15 percent on Monday after the company's January-March results beat street estima...
- Divis Labs Q3 net up 45.07 pc to Rs 98.42 crDrug firm Divis Laboratories today said its consolidated net profit rose by 45.07 per cent to Rs 98.42 crore for the third quarter ended De...
Load More
